Case-control study of debrisoquine 4-hydroxylase, n-acetyltransferase 2, and apolipoprotein e gene polymorphisms in Parkinson's disease

• Published in: Movement disorders 2000-07, Vol.15 (4), p.714-719
• Main Authors: Maraganore, Demetrius M., Farrer, Matthew J., Hardy, John A., McDonnell, Shannon K., Schaid, Daniel J., Rocca, Walter A.
• Format: Article
• Language: English
• Subjects: Adult; Aged; Aged, 80 and over; Alleles; APOE; Apolipoproteins E - genetics; Arylamine N-Acetyltransferase - blood; Arylamine N-Acetyltransferase - genetics; Biological and medical sciences; Case-Control Studies; Case-control study; CYP2D6; Cytochrome P-450 CYP2D6 - blood; Cytochrome P-450 CYP2D6 - genetics; Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases; Female; Genotype; Humans; Male; Medical sciences; Middle Aged; NAT2; Neurology; Parkinson Disease - diagnosis; Parkinson Disease - enzymology; Parkinson Disease - genetics; Parkinson's disease; Polymorphism, Genetic - genetics; Susceptibility genes
• ISSN: 0885-3185; 1531-8257
• DOI: 10.1002/1531-8257(200007)15:4<714::AID-MDS1018>3.0.CO;2-3

We investigated the association of Parkinson's disease (PD) with two genes encoding liver‐detoxifying enzymes, debrisoquine 4‐hydroxylase (CYP2D6) and N‐acetyltransferase 2 (NAT2), and with one gene related to Alzheimer's disease, apolipoprotein E (APOE). In a sample of 139 unrelated PD cases and 113 control subjects, the NAT2 M3 allele was associated with PD (odds ratio = 7.9; 95% confidence interval = 1.7–36.3). Case‐control analyses for CYP2D6, APOE, and NAT2 M1 or M2 did not show a significant association. However, the age at onset of PD was significantly earlier in cases with the APOE ϵ2/ϵ3 genotype than in cases with the ϵ3/ϵ3 genotype.